HESCHI H. ROTMENSCH, M.D.; URI ELKAYAM, M.D.; WILLIAM FRISHMAN, M.D.
Pregnancy increases the work demands on the heart by increasing blood volume and thereby cardiac output. Therefore, in pregnant patients with organic heart disease, arrhythmias may have significant hemodynamic consequences to the mother with harm to the fetus. As a result of improved medical therapy, an increasing number of women with cardiac diseases or rhythm disorders reach their reproductive years and require medication. Information on the effect of antiarrhythmic agents on the human fetus as well as the possible changes in therapeutic response during the altered state of pregnancy is limited. In principle, the approach to the treatment of arrhythmias in pregnant patients is similar to that in nonpregnant patients. Special consideration, however, must be given with regard to drug selection and dosage in order to avoid adverse effects on the mother and fetus.
HESCHI H. ROTMENSCH, URI ELKAYAM, WILLIAM FRISHMAN. Antiarrhythmic Drug Therapy During Pregnancy. Ann Intern Med. 1983;98:487–497. doi: 10.7326/0003-4819-98-4-487
Download citation file:
Published: Ann Intern Med. 1983;98(4):487-497.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use